|
EP0091240B1
(en)
*
|
1982-04-07 |
1985-12-27 |
Beecham Group Plc |
Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
|
|
EP0125269A1
(en)
*
|
1982-11-11 |
1984-11-21 |
Beecham Group Plc |
Pharmaceutically active compounds
|
|
GB8400653D0
(en)
*
|
1984-01-11 |
1984-02-15 |
Beecham Group Plc |
Conjugates
|
|
GB8430253D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
|
US5231006A
(en)
*
|
1986-10-16 |
1993-07-27 |
Behringwerke Aktiengesellschaft |
Method for the determination of plasminogen
|
|
US5256642A
(en)
*
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
JPH0296536A
(ja)
*
|
1988-09-29 |
1990-04-09 |
Green Cross Corp:The |
プラスミノゲン乾燥製剤
|
|
AU647391B2
(en)
*
|
1989-05-01 |
1994-03-24 |
University Of Notre Dame Du Lac, The |
Methods and materials for expression of human plasminogen in a eukaryotic cell system
|
|
EP0397366A1
(en)
*
|
1989-05-09 |
1990-11-14 |
The Board Of Regents Of The University Of Oklahoma |
Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
|
|
DE69025934T2
(de)
*
|
1989-05-17 |
1996-09-19 |
Res Corp Technologies Inc |
Verfahren und zusammensetzung zur thrombosebehandlung beim säugetier
|
|
CA2027936C
(en)
|
1989-10-23 |
2001-07-24 |
Smithkline Beecham Corporation |
Cyclic anti-aggregatory peptides
|
|
US5190756A
(en)
*
|
1989-12-01 |
1993-03-02 |
Genentech, Inc. |
Methods and materials for expression of human plasminogen variant
|
|
US5087572A
(en)
*
|
1989-12-01 |
1992-02-11 |
Genentech, Inc. |
Dna encoding human plasminogen modified at the cleavage site
|
|
GB8928163D0
(en)
*
|
1989-12-13 |
1990-02-14 |
Beecham Group Plc |
Novel treatment
|
|
US6458360B1
(en)
|
1990-04-25 |
2002-10-01 |
The Johns Hopkins University |
Soluble complement regulatory molecules
|
|
US5187069A
(en)
*
|
1990-08-06 |
1993-02-16 |
Henry Ford Health System |
Active site labelling of plasminogen
|
|
WO1992018139A1
(en)
*
|
1991-04-09 |
1992-10-29 |
Brigham And Women's Hospital |
Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
|
|
US5520912A
(en)
*
|
1993-07-02 |
1996-05-28 |
Immuno Aktiengesellschaft |
Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
|
|
DE4411143C2
(de)
*
|
1994-03-30 |
1996-08-01 |
Immuno Ag |
Thrombosemittel
|
|
US5760028A
(en)
*
|
1995-12-22 |
1998-06-02 |
The Dupont Merck Pharmaceutical Company |
Integrin receptor antagonists
|
|
US6004955A
(en)
*
|
1996-08-15 |
1999-12-21 |
Dupont Pharmaceuticals Company |
Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
|
|
WO1998057937A2
(en)
|
1997-06-19 |
1998-12-23 |
The Du Pont Merck Pharmaceutical Company |
Inhibitors of factor xa with a neutral p1 specificity group
|
|
WO2001009188A1
(en)
*
|
1999-07-29 |
2001-02-08 |
Dyax Corp. |
Binding moieties for fibrin
|
|
US6388073B1
(en)
|
2000-07-26 |
2002-05-14 |
Shire Us Inc. |
Method for the manufacture of anagrelide
|
|
KR20010000669A
(ko)
*
|
2000-10-12 |
2001-01-05 |
김기환 |
스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
|
|
US6984373B2
(en)
*
|
2000-12-23 |
2006-01-10 |
Dyax Corp. |
Fibrin binding moieties useful as imaging agents
|
|
MEP58108A
(en)
|
2001-09-21 |
2011-05-10 |
Bristol Myers Squibb Co |
Lactam-containing compounds and derivatives thereof as factor xa inhibitors
|
|
US7550499B2
(en)
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
US20060030574A1
(en)
*
|
2004-08-04 |
2006-02-09 |
Shire Holdings Ag |
Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
|
|
US7700608B2
(en)
*
|
2004-08-04 |
2010-04-20 |
Shire Holdings Ag |
Quinazoline derivatives and their use in the treatment of thrombocythemia
|
|
US7459564B2
(en)
|
2005-01-13 |
2008-12-02 |
Bristol-Myers Squibb Company |
Substituted biaryl compounds as factor XIa inhibitors
|
|
WO2006078621A2
(en)
|
2005-01-19 |
2006-07-27 |
Bristol-Myers Squibb Company |
2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
|
|
AU2006261828A1
(en)
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
US7714002B2
(en)
|
2005-06-27 |
2010-05-11 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
DE602006017694D1
(de)
|
2005-06-27 |
2010-12-02 |
Bristol Myers Squibb Co |
C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
|
|
US7816382B2
(en)
|
2005-06-27 |
2010-10-19 |
Bristol-Myers Squibb Company |
Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
|
|
CN101500993A
(zh)
|
2006-06-08 |
2009-08-05 |
百时美施贵宝公司 |
作为凝血因子Ⅶa抑制剂用作抗凝血药的2-氨基羰基苯基氨基-2-苯基乙酰胺
|
|
US7960569B2
(en)
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
US7910597B2
(en)
*
|
2006-11-28 |
2011-03-22 |
Shire Llc |
Substituted quinazolines
|
|
US8304420B2
(en)
|
2006-11-28 |
2012-11-06 |
Shire Llc |
Substituted quinazolines for reducing platelet count
|
|
WO2008076805A2
(en)
|
2006-12-15 |
2008-06-26 |
Bristol-Myers Squibb Company |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
|
|
PE20081775A1
(es)
|
2006-12-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
|
TW200848024A
(en)
|
2007-06-13 |
2008-12-16 |
Bristol Myers Squibb Co |
Dipeptide analogs as coagulation factor inhibitors
|
|
US20090130017A1
(en)
*
|
2007-11-19 |
2009-05-21 |
Searete Llc |
Targeted short-lived drug delivery
|
|
JP5504259B2
(ja)
|
2008-05-19 |
2014-05-28 |
メルク・シャープ・アンド・ドーム・コーポレーション |
第ｉｘａ因子阻害剤としての複素環式化合物
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
US8609676B2
(en)
|
2009-08-04 |
2013-12-17 |
Merck Sharp & Dohme, Corp. |
4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
|
|
US8940720B2
(en)
|
2010-02-11 |
2015-01-27 |
Bristol-Myers Squibb Company |
Macrocycles as factor XIa inhibitors
|
|
TW201319068A
(zh)
|
2011-08-05 |
2013-05-16 |
必治妥美雅史谷比公司 |
作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
|
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子ｘｉａ抑制劑之新穎巨環化合物
|
|
IN2014CN02806A
(no)
|
2011-10-14 |
2015-07-03 |
Bristol Myers Squibb Co |
|
|
WO2013056034A1
(en)
|
2011-10-14 |
2013-04-18 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
|
CN103974938B
(zh)
|
2011-10-14 |
2016-11-09 |
百时美施贵宝公司 |
作为因子xia抑制剂的经取代的四氢异喹啉化合物
|
|
CN103917529B
(zh)
|
2011-11-11 |
2016-08-17 |
辉瑞大药厂 |
2-硫代嘧啶酮类
|
|
JP2015515472A
(ja)
|
2012-04-06 |
2015-05-28 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ２阻害薬
|
|
JP6082463B2
(ja)
|
2012-08-03 |
2017-02-15 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１
|
|
SG11201500270RA
(en)
|
2012-08-03 |
2015-03-30 |
Bristol Myers Squibb Co |
Dihydropyridone p1 as factor xia inhibitors
|
|
JP6479763B2
(ja)
|
2013-03-25 |
2019-03-06 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
|
|
WO2015052610A1
(en)
|
2013-10-09 |
2015-04-16 |
Pfizer Inc. |
Antagonists of prostaglandin ep3 receptor
|
|
ES2893251T3
(es)
|
2014-01-31 |
2022-02-08 |
Bristol Myers Squibb Co |
Macrociclos con grupos P2 heterocíclicos como inhibidores del factor XIa
|
|
NO2760821T3
(no)
|
2014-01-31 |
2018-03-10 |
|
|
|
CR20160405A
(es)
|
2014-03-17 |
2016-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
DK3126330T3
(en)
|
2014-04-04 |
2019-04-23 |
Pfizer |
BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
|
|
EP3131897B8
(en)
|
2014-04-16 |
2022-08-03 |
Merck Sharp & Dohme LLC |
Factor ixa inhibitors
|
|
NO2721243T3
(no)
|
2014-10-01 |
2018-10-20 |
|
|
|
MX382097B
(es)
|
2015-05-05 |
2025-03-13 |
Pfizer |
1-(2-aminoetil)-6-(2-(2-hidroxietoxi)-5-metilfenil)-2-tioxo-2,3-dihidropirimidin-4(1h)-ona, y el uso del mismo para tratar afecciones cardiovasculares.
|
|
CU20170153A7
(es)
|
2015-06-17 |
2018-01-10 |
Pfizer |
Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
JP6816103B2
(ja)
|
2015-07-29 |
2021-01-20 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
非芳香族性Ｐ２’基を担持する新規大員環の第ＸＩａ因子阻害剤
|
|
CN108137549B
(zh)
|
2015-08-05 |
2021-07-20 |
百时美施贵宝公司 |
取代的甘氨酸衍生的fxia抑制剂
|
|
HK1254323A1
(zh)
|
2015-08-27 |
2019-07-19 |
辉瑞公司 |
作為irak4調節劑的雙環稠合雜芳基或芳基化合物
|
|
EP3423458A1
(en)
|
2016-03-02 |
2019-01-09 |
Bristol-Myers Squibb Company |
Diamide macrocycles having factor xia inhibiting activity
|
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
|
WO2020044266A1
(en)
|
2018-08-31 |
2020-03-05 |
Pfizer Inc. |
Combinations for treatment of nash/nafld and related diseases
|
|
CA3140972C
(en)
|
2019-05-20 |
2024-06-18 |
Pfizer Inc. |
Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
|
|
JP2023534704A
(ja)
|
2020-07-22 |
2023-08-10 |
ヤンセン ファーマシューティカ エヌ．ベー． |
第ｘｉａ因子阻害剤として有用な化合物
|
|
WO2023026180A1
(en)
|
2021-08-26 |
2023-03-02 |
Pfizer Inc. |
Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
|
|
WO2024118524A1
(en)
|
2022-11-28 |
2024-06-06 |
Cerevel Therapeutics, Llc |
Azaindole compounds and their use as phosphodiesterase inhibitors
|